BARDA Grants IAVI $36 Million for Single-Dose Bundibugyo Ebola Vaccine Development

IAVI and partners received $36 million from BARDA to accelerate development, manufacturing, and clinical evaluation of a one-dose vaccine candidate for the Bundibugyo virus (BDBV). This virus is causing an ongoing Ebola epidemic in the DRC, exceeding 10,000 cases. The funding supports manufacturing for clinical evaluation, including a Phase 1 trial, and aims to address the urgent need for an approved BDBV vaccine or treatment.